Respiratory drug may be withdrawn

The challenges posed by pharmaceutical companies seeking massive reimbursement for life-changing drugs has led to a second situation this week where patients face losing access to vital treatment.
Respiratory drug may be withdrawn

The threat by drug firm CSL Behring to withdraw Respreeza, described by respiratory consultant Gerry McElvaney as “the only treatment for genetic emphysema in my lifetime”, follows a decision by the National Centre for Pharmacoeconomic Evaluation (NCPE) not to recommend State reimbursement of the drug.

The decision has led to calls for Health Minister Simon Harris to intervene on behalf of those with genetic emphysema, known as Alpha-1.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited